


PHARMACEUTICAL 2018


MusclePharm Corp Rank 154 of 349







PHARMACEUTICAL 2018





The relative strengths and weaknesses of MusclePharm Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MusclePharm Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 859% points. The greatest weakness of MusclePharm Corp is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 698% points.

The company's Economic Capital Ratio, given in the ranking table, is -143%, being 135% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	30,462
Cost of Goods Sold	71,710
Intangible Assets	1,317
Liabilities, Current	28,483
Liabilities, Non-Current	0
Other Assets	225
Other Compr. Net Income	0
Other Expenses	24,813
Other Liabilities	17,877
Other Net Income	-3,642
Property and Equipment	1,822
Research and Development	642
Revenues	102,155
Selling, General and Administrative Expense	12,071

Output Variable	Value in 1000 USD
Assets	33,826
Liabilities	46,360
Expenses	109,236
Stockholders Equity	-12,534
Net Income	-10,723
Comprehensive Net Income	-10,723
Economic Capital Ratio	-143%